Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01818076 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.

NCT NCT01818076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01818076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
Lead sponsor
Revance Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2013
Completion date
December 31, 2013
Enrollment
311 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin aging